Class action lawsuit targets PomDoctor over alleged securities fraud between Oct. 9 and Dec. 11, 2025

Reuters03-13 00:01
Class action lawsuit targets PomDoctor over alleged securities fraud between Oct. 9 and Dec. 11, 2025

A securities class action lawsuit has been filed against PomDoctor and certain officers, alleging violations of U.S. federal securities laws. The suit seeks damages for investors who bought or acquired PomDoctor securities between Oct. 9, 2025 and Dec. 11, 2025. The complaint alleges PomDoctor was tied to a fraudulent stock promotion scheme involving social media misinformation and impersonated financial professionals. It also alleges insiders or affiliates used offshore or nominee accounts to coordinate share sales during a period of alleged price inflation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pomdoctor Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603121200PRIMZONEFULLFEED9668442) on March 12, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment